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Summary points
• The ever-growing HIV treatment programs in sub-Saharan Africa (SSA) present local
policy makers with complex decision dilemmas, as international guidelines emphasize
the need for expanded access to antiretroviral therapy (ART), yet funding has flatlined.
• We argue that the current evidence base for prioritizing ART scale-up strategies results in
recommendations that are theoretically optimal but practically infeasible to implement.
• Cost-effectiveness analyses (CEAs) of scaling up ART in SSA should be made more
responsive to the needs of policy makers by taking into account the local health system.
• We provide suggestions for a better integration of health system constraints into CEA
by integrating supply- and demand-side constraints in mathematical models and
improving the dialogue between researchers and policy makers.
Introduction
The scale-up of antiretroviral therapy (ART) for HIV-infected people in sub-Saharan Africa
(SSA) over the past 15 years is one of the most remarkable achievements in public health. With
approximately 12 million people on treatment in 2015, life expectancy on the subcontinent has
vastly improved [1]. Nevertheless, ART coverage in SSA is still suboptimal, HIV incidence
remains high [1], and improved survival due to ART implies ever increasing numbers of peo-
ple on treatment [2]. Substantial additional resources are needed to further scale up ART, yet
funding has levelled off over the recent years, increasing the need for optimizing the allocation
of limited resources [3].
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The evidence base for resource allocation for strategies to scale up HIV treatment—e.g., on
eligibility for treatment initiation—largely consists of cost-effectiveness analyses (CEAs) [4]. We
reviewed the literature and found a total of 34 modelling studies performing prospective popu-
lation-level CEAs on strategies of scaling up ART in SSA (S1 Text). Many of these strategies,
e.g., universal testing and immediate treatment for all HIV-infected people, require substantial
investments, yet most of the models implicitly assumed a well-functioning health system with
unlimited resources by modelling immediate and sustainable implementation. In reality, most
health systems experience constraints on the supply side (i.e., the capacity of the health system)
and on the demand side (i.e., demand of HIV-infected people to receive care) (Box 1). In our
review, no studies incorporated a comprehensive set of health system constraints. While 11
included some elements of demand-side constraints, only 4 incorporated some sort of supply-
side constraint, and none incorporated a comprehensive set of both types of constraints.
Here, we call for a more policy-relevant, integrated approach to CEA that incorporates
health system constraints for two important reasons: (1) to determine more realistically the
cost-effectiveness of the implementation of HIV treatment strategies within existing constraints
and (2) to incorporate the resource needs, effects, and cost-effectiveness of overcoming con-
straints. For instance, health worker constraints could hamper the successful implementation
of the WHO treatment recommendation of ART eligibility for all HIV-infected individuals, as
the increase in eligible patients would necessitate more doctors and nurses. Implementation
would require training of health workers, which introduces a time lag and requires financial
investments, available human capital, and sufficient training capacity. CEA not performed in
the context of these constraints may result in recommendations that are theoretically optimal
but practically infeasible to implement [7]. In addition, the resources and time required to
overcome constraints could be substantial and could make suggested HIV treatment strategies
far less cost-effective than in hypothetical optimal settings of unlimited resources.
Health system constraints
Supply-side constraints can be described in terms of the six health system building blocks as put
forward by WHO [8]. These are (1) adequate service delivery—i.e., the availability of good,
timely, and sustainable care to all patients along the full cascade of care; (2) a sufficient number
of qualified health workers to provide treatment and care to all eligible patients; (3) a health infor-
mation system that monitors health system performance and systematically records essential
information on all patients—for example, to identify and respond to areas of underperformance
or to improve re-enrolment of patients who defaulted treatment; (4) a reliable supply chain
Box 1. Health system constraints
Supply-side constraints are defined as barriers in the capacity of the health system that
hamper the delivery of care. For instance, drug stock outs at ART clinics in SSA are com-
monly reported, resulting in clinics being unable to distribute drugs to patients and
thereby disrupting the continuum of care [5].
Demand-side constraints are defined as barriers that affect the demand for care of
people who would be eligible for a certain treatment or intervention. Commonly
reported demand-side constraints in ART delivery are simply forgetting to visit the clinic
or take medications, being away from home, changes in daily routine, stigma, or travel
costs [6].
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management of medical products and technologies to ensure sufficient supply of drugs and medi-
cal equipment; (5) sustainable financing to maintain care and treatment for those eligible; and
(6) good governance that allows balanced, contextual decisions in allocating and managing lim-
ited resources.
Successful implementation of HIV treatment strategies is also determined by demand-side
constraints. Stigma, limited knowledge about HIV, fatalism, out-of-pocket payments, and
waiting times can affect health care-seeking behaviours such as consenting to testing, treat-
ment uptake, and adherence. These constraints are all related to disease stage, as people who
are at a relatively early stage of infection experience fewer symptoms and thus may be less
motivated to seek care.
Supply- and demand-side constraints introduce complex, interrelated dynamics. Because of
economies of scale and scope and interdependencies between supply and demand, changes in
the number of people on ART rarely translate into a linear change in the need for financial,
infrastructural, and human resources to provide the required services [9]. For instance,
increased awareness of the benefits of HIV treatment—e.g., through visible improvements in
the health of community members—may result in increased demand. In turn, increased
demand may improve efficiency through economies of scale or result in overstretched
resources and diseconomies of scale when resources are insufficient [9]. Furthermore, the rela-
tive impact of health system constraints is sensitive to time, context, and type of intervention.
Constraints may change over time, e.g., the number of people on treatment may decrease as an
effect of reduced incidence. Also, constraints are geographically heterogeneous, e.g., between
rural and urban areas. Finally, certain health system constraints are more relevant to specific
interventions; for example, community-based ART delivery requires different types of
resources compared to clinic-based ART delivery. Because of these complex dynamics, con-
straints cannot be interpreted in isolation—for instance, as separate criteria in a policy process
—but should be explicitly integrated within CEA.
Moving forward
Some mathematical modelling studies have explored the effects of constraints on the cost-
effectiveness of ART treatment strategies in SSA. Cleary et al., Fraser et al., and Anderson et al.
determined the optimal treatment strategies within the available budgets for South Africa [10],
Nigeria [11], and Kenya [12], respectively. Recently, Hontelez et al. determined the cost-effec-
tiveness of ART for all HIV-infected people within different scenarios of supply- and demand-
side constraints for ten countries in SSA [2]. Although we applaud these efforts, the extent to
which they incorporated constraints is limited.
In order to move towards more realistic and policy-relevant CEAs, methodological innova-
tions that include a more complete set of health system constraints into mathematical models
are needed. Financial, infrastructural, and human resources required for alternative strategies
need to be explicitly incorporated in a dynamic way. Supply-side constraints should not be
treated statically—e.g., by simply assuming a maximum number of people who can receive
ART. Rather, the effects of insufficient resources should dynamically translate into reduced
performance along the full cascade of care in order to adequately reflect the patient- and popu-
lation-level effects of policy decisions. For instance, the effect of undercapacity—i.e., when the
number of people on treatment exceeds the capacity of the available health workers—could
dynamically translate into lower adherence and higher attrition rates of people on ART. Like-
wise, demand-side dynamics along the full cascade of care should reflect the tendency of indi-
viduals to test, link, and adhere to treatment as a function of disease stage, health system
access, and perceived quality of services.
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We realize that the development of such models requires extensive efforts to improve
empirical evidence of the underlying dynamics. Some descriptive data on health system con-
straints are available, and we know that poor adherence, unsuppressed viral loads, and high
rates of attrition are signs of suboptimal treatment programs [13]. However, causal relation-
ships describing the interactions between these constraints as well as their impact on the effec-
tiveness of an HIV treatment program have yet to be quantified. For instance, the quantitative
relationship between undercapacity and poor adherence is not yet fully understood. Reanalysis
of existing data from longitudinal cohorts or including health system components in experi-
mental designs could help to close this gap in knowledge. For instance, the ongoing cluster-
randomized trials on treatment as prevention in SSA offer the opportunity to compare the out-
comes of treatment programs among clinics with different capacities and among sites that use
different treatment guidelines. Also, qualitative and quantitative data collection by interview-
ing patients could further increase the understanding of how supply-side dynamics and con-
straints affect patient behaviour.
Mathematical modelling also offers the opportunity to explore the impact of constraints
even when precise estimates of the strengths of these relationships are unknown, e.g., through
scenario and sensitivity analyses. These will be informative for policy makers by offering a
range of expected outcomes under different constraints; in turn, they may incentivise further
data collection by identifying key dynamic drivers that influence the outcome of CEAs. Future
CEAs in HIV treatment and care should therefore include such explorative analyses, even
when detailed data are not available.
Developing evidence that is more responsive to its decision context requires intensified col-
laboration between local policy makers and researchers. This is essential to formulate relevant
research questions and assess what evidence is needed and which health system constraints
would need to be taken into account. Finally, while improved CEA leads to a better evidence
base for scaling up HIV treatment, it should be considered as only one input in the decision-
making process. Other considerations, such as the preference of society to prioritise HIV treat-
ment for the worse off or to reduce stigma, cannot be captured in a CEA. Fair decision-making
processes, involving all relevant stakeholders, provide a means to take such considerations into
account, in conjunction with evidence on cost-effectiveness [14].
Conclusion
CEAs of scaling up HIV treatment in SSA should be made more responsive to the needs of pol-
icy makers by taking into account the local health system context. We call for a better integra-
tion of health system constraints into CEA—by accounting for such constraints in the use of
mathematical models, facilitated by a dialogue between researchers and policy makers. This
will result in CEA for HIV treatment strategies that are more policy relevant, allowing policy
makers in SSA countries to make feasible choices for scaling up ART. Finally, lessons learned
from improved CEAs in ART scale-up can also be applied to other disease areas that face simi-
lar dilemmas, such as malaria, tuberculosis, and noncommunicable diseases, and can help
researchers and policy makers to better understand the impact of integration and decentraliza-
tion of services across disease areas.
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S1 Text. A systematic literature review of modelling studies performing prospective popu-
lation level CEA of HIV treatment strategies in SSA.
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